Acumen Pharmaceuticals, Inc. (ABOS) vs Humacyte, Inc. (HUMA)

Acumen Pharmaceuticals, Inc. and Humacyte, Inc. are both Biotechnology companies. Acumen Pharmaceuticals, Inc. and Humacyte, Inc. are of similar size ($166.7M and $161.6M). Acumen Pharmaceuticals, Inc. has the higher net margin (0.00% vs −4,448.9%) and the higher return on invested capital (0.00% vs −433.7%). Across the 16 metrics below, Acumen Pharmaceuticals, Inc. leads on 10 and Humacyte, Inc. on 6.

Valuation

Metric ABOS HUMA Biotechnology median
P/E n/m n/m 7.88
P/S 112.70 61.83 11.47
P/B 2.83 4.20 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 57.95 55.84 10.73
Earnings yield (72.77%) (87.50%) (28.84%)
Free cash flow yield (56.77%) (74.39%) (23.03%)

Profitability

Metric ABOS HUMA Biotechnology median
Gross margin 0.00% (494.58%) 65.16%
Operating margin 0.00% (5,240.78%) 0.00%
Net margin 0.00% (4,448.89%) 0.00%
Free cash flow margin 0.00% (4,599.72%) 0.00%
Return on equity (120.50%) (534.42%) (57.72%)
Return on assets (72.97%) (68.16%) (49.22%)
Return on invested capital 0.00% (433.66%) 0.00%

Growth

Metric ABOS HUMA Biotechnology median
Revenue growth (TTM) — 149.82% 5.64%
EPS growth (last fiscal year) (16.96%) 79.37% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABOS HUMA Biotechnology median
Debt to equity 0.55 2.07 0.00
Current ratio 2.47 6.21 4.73
Net debt to EBITDA 0.69 (0.12) 0.96

Dividend

Metric ABOS HUMA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ABOS HUMA Biotechnology median
Market cap 161.63m 166.65m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack